Billions in biotech investment disappear each year via stalled research and shelved assets. Zlatomics Fintech brings that capital back.
Secure Early AccessWe envision a biotech economy where no validated science goes to waste — where every researcher's data has a financial future, and where capital flows back into discovery rather than disappearing from it.
Conventional finance has no framework for assets that don't fit a binary outcome. When a drug trial fails or a program is shelved, the accounting closes — even when the underlying data, IP, or science retains real value. The system isn't designed to find it.
Zlatomics Fintech applies a proprietary framework to recapture value from biotech assets the market has written off — re-engaging dormant assets and channeling recovered capital back into the productive economy.
We identify undervalued and written-off biotech assets — failed programs, shelved IP, and stranded scientific work with latent economic value.
Asset DiscoveryOur proprietary mechanism re-evaluates these assets through a new lens, opening value that conventional finance overlooks.
Proprietary ProcessRecovered value is channeled back into productive use — reinvestment in science, returns to stakeholders, and a healthier, more efficient biotech ecosystem.
Economic RecoveryRequest more information, updates, and early access.